Bacillus calmette-guerin substrain danish 1331 live antigen
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Bacillus calmette-guerin substrain danish 1331 live antigen
- DrugBank Accession Number
- DB12386
- Background
BCG SSI has been used in trials studying Tuberculosis.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Vaccines
Other vaccines - Synonyms
- BCG (SSI strain)
- BCG SSI
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Abatacept. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Bacillus calmette-guerin substrain danish 1331 live antigen. Aldesleukin The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Alemtuzumab. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 4CGF0IDN3W
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347911329
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Recruiting Prevention Infant Death / Morbidity;Infant / Neonatal Mortality / Newborn Morbidity / Non Specific Effects of Vaccine 1 3 Completed Prevention BCG Vaccination Reaction / Tuberculosis (TB) 1 3 Completed Prevention Coronavirus Disease 2019 (COVID‑19) / Immunity, Heterologous / Immunosenescence / Morbidity / Non Specific Effects of Vaccine / Vaccine Preventable Diseases 1 2 Completed Prevention Tuberculosis (TB) 1 1 Completed Prevention Tuberculosis (TB) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Intradermal 0.75 mg/ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at October 20, 2016 22:10 / Updated at June 12, 2020 16:53